Strawberry Hill

Strawberry Hill ID was a clinical-stage biotechnology company focused on developing novel therapies for infectious diseases, with a primary emphasis on chronic hepatitis B virus (HBV) infection. Founded by former executives from Assembly Biosciences, the company specialized in the discovery of next-generation capsid assembly modulators (CAMs) designed to achieve a functional cure for HBV. Its research programs aimed to disrupt the viral replication cycle and reduce the viral reservoir in the liver. In early 2024, the company was acquired by Arbutus Biopharma to bolster its portfolio of HBV-targeted therapeutics. The acquisition integrated Strawberry Hill's expertise in antiviral drug design into Arbutus's broader mission of curing chronic HBV.